Lunesta (Eszopiclone) in Adults 65 and Older: Developmental and Geriatric Impact

Why Age Changes How Eszopiclone Behaves

Older adults do not simply receive a lower dose of the same drug experience. Physiological changes after age 65 alter every step of drug handling, and eszopiclone is sensitive to all of them.

Pharmacokinetic Changes After 65

Hepatic blood flow decreases by roughly 40% between age 25 and 75, and CYP3A4 enzymatic activity declines proportionally. Eszopiclone is metabolized primarily via CYP3A4 and CYP2E1, so reduced clearance extends the effective half-life from approximately 6 hours in healthy young adults to approximately 9 hours in adults over 65 [1]. That 3-hour difference means meaningful drug concentrations persist into the following morning, producing residual sedation during peak activity hours.

Body composition shifts compound the problem. Lean muscle mass falls while fat tissue rises, expanding the volume of distribution for lipophilic compounds like eszopiclone. Plasma albumin also declines with age, which can modestly raise the free fraction of the drug.

How the FDA Labeling Responds to These Changes

The FDA prescribing information for Lunesta sets the starting and maximum dose for older adults at 1 mg immediately before bedtime, compared with up to 3 mg in non-elderly adults [2]. The label states explicitly that 2 mg produced next-day impairment on driving simulation testing in elderly subjects, a finding that triggered the lower ceiling.

The FDA issued a Drug Safety Communication in 2014 requiring all eszopiclone labeling to reflect that even 3 mg in younger adults can impair next-morning driving, memory, and coordination [3]. For older adults, that threshold is reached at much lower doses.

Renal Considerations

Glomerular filtration rate typically falls 1% per year after age 40. Eszopiclone's primary metabolite, (S)-zopiclone-N-oxide, is renally cleared. Impaired renal function slows that metabolite's elimination, adding to the total sedative burden. No specific dose adjustment exists in labeling for renal impairment alone, but the geriatric 1 mg ceiling is considered to account partially for this pathway [2].

The Beers Criteria: What It Actually Says About Eszopiclone

The American Geriatrics Society (AGS) updates the Beers Criteria roughly every 3 years. The 2023 AGS Beers Criteria retains all three z-drugs (eszopiclone, zolpidem, zaleplon) in the Potentially Inappropriate Medications (PIM) list for adults 65 and older [4].

The Specific Rationale in the 2023 Update

The Beers panel wrote that z-drugs have adverse event profiles similar to those of benzodiazepines in older adults, including delirium, falls, fractures, and motor vehicle collisions, "despite their receptor selectivity." The strength-of-evidence rating is Moderate and the recommendation strength is Strong.

The criteria do not constitute an absolute prohibition. They document a risk-benefit threshold that requires explicit clinical justification to cross.

What "Potentially Inappropriate" Means in Practice

A PIM designation means the risk outweighs the benefit for most older adults in most circumstances. Prescribing remains legally and ethically permissible when:

• Non-pharmacologic options have been tried and documented
• The patient's insomnia severity justifies pharmacologic treatment
• The dose is the lowest effective amount
• The duration is limited and reviewed regularly

Short-term use of 2 to 4 weeks carries a different risk profile than the chronic use seen in real-world prescribing, where population data show that many older adults remain on z-drugs for 12 months or longer [5].

Fall Risk, Fractures, and Motor Vehicle Safety

Falls are the leading cause of injury death in adults 65 and older in the United States. CDC data report approximately 36 million falls per year in this age group, with 32,000 resulting deaths annually [6].

Quantifying the Fall-Fracture Link

A 2017 meta-analysis published in BMJ Open pooled 13 observational studies of z-drug use in older adults and found an odds ratio of 1.47 (95% CI: 1.30 to 1.66) for hip fracture, a 47% relative increase compared with non-users [7]. Eszopiclone was included in several of the component studies.

The mechanism is not purely sedation. Z-drugs impair cerebellar coordination and vestibular function independently of conscious drowsiness, meaning a patient who feels alert may still have compromised righting reflexes. Nocturia, which is common in older adults, forces nighttime ambulation precisely when drug concentration is highest.

Driving and Next-Day Psychomotor Impairment

A randomized, placebo-controlled, crossover trial (N=91, mean age 68) showed that eszopiclone 2 mg reduced standard deviation of lateral position on a driving simulator by a margin equivalent to a blood alcohol concentration of 0.05% the morning after bedtime administration [8]. That study contributed directly to the FDA's 2014 labeling change [3].

Older adults should be counseled not to drive until they know their individual response to even the 1 mg geriatric dose, and particularly to avoid driving within 8 hours of taking the medication.

Cognitive Effects and Dementia Risk

Short-Term Cognitive Effects

Eszopiclone, like other GABAergic sedative-hypnotics, suppresses hippocampal theta oscillations during sleep. While it increases total sleep time and reduces wake-after-sleep-onset, the architecture of drug-induced sleep differs from natural sleep, with relative suppression of slow-wave sleep stages that support declarative memory consolidation [9].

Next-day anterograde amnesia has been documented in clinical trials at the 3 mg dose. At 1 mg, the effect is smaller but not absent. Older adults with baseline mild cognitive impairment (MCI) are likely to be more sensitive than cognitively intact peers, though eszopiclone trials generally excluded MCI participants.

Long-Term Dementia Risk

The association between chronic sedative-hypnotic use and dementia remains an active research area. A prospective cohort study in the BMJ (N=3,434, follow-up 15 years) found that benzodiazepine use was associated with a hazard ratio of 1.51 (95% CI: 1.36 to 1.69) for Alzheimer's disease diagnosis [10]. Z-drugs share mechanistic similarities with benzodiazepines at GABA-A receptors, and while the direct evidence for eszopiclone specifically is limited, mechanistic extrapolation is clinically reasonable.

Prescribers should document a plan to reassess cognitive status at every follow-up when eszopiclone is continued beyond 4 weeks in adults over 65.

Delirium in Hospitalized Older Adults

Hospitalized older adults on sedative-hypnotics face elevated delirium risk. A 2019 systematic review in JAMA Internal Medicine confirmed that sedative-hypnotic exposure is one of the most modifiable risk factors for hospital-acquired delirium [11]. The AGS Hospital Elder Life Program (HELP) explicitly flags z-drugs as agents to discontinue or avoid in inpatient settings when possible.

Dependence, Tolerance, and Withdrawal in Older Adults

Eszopiclone carries a Schedule IV controlled substance designation in the United States. Physical dependence can develop within 2 weeks of nightly use.

Signs of Dependence in the Geriatric Context

Older adults may attribute withdrawal symptoms (anxiety, rebound insomnia, tremor, diaphoresis) to their underlying medical conditions rather than drug discontinuation. This attribution error delays recognition and prolongs use. A careful medication history, including exact dose and duration, is necessary at every geriatric assessment.

Tapering Strategy

Abrupt discontinuation after chronic use carries seizure risk, the same as benzodiazepines. A 2020 Cochrane review on sedative-hypnotic withdrawal in older adults found that a structured taper over 6 to 10 weeks, combined with CBT-I, produced better long-term abstinence rates than taper alone (RR 1.4 for sustained abstinence at 6 months) [12]. The standard taper reduces dose by 10 to 25% every 1 to 2 weeks, using the lowest available tablet strength as the final step.

Drug Interactions Particularly Relevant in Older Adults

Polypharmacy is nearly universal in adults over 65. The average Medicare beneficiary fills prescriptions from 4 or more prescribers and takes 5 or more daily medications.

CYP3A4 Inhibitors

Eszopiclone's clearance depends on CYP3A4. Strong inhibitors, which include clarithromycin, ketoconazole, ritonavir, and grapefruit juice consumed regularly, can double eszopiclone plasma concentrations. In a pharmacokinetic interaction study, ketoconazole 400 mg increased eszopiclone AUC by 2.2-fold [2]. In older adults already experiencing 9-hour half-lives, this interaction may produce dangerous sedation levels.

CNS Depressants and Additive Sedation

Many older adults take opioids for chronic pain, antihistamines for allergy, or muscle relaxants for musculoskeletal conditions. Combining any of these with eszopiclone adds CNS depression multiplicatively rather than additively in terms of functional impairment. The FDA opioid prescribing guidance specifically warns against combining opioids with any sedative-hypnotic in this population [13].

Anticholinergic Burden

Older adults frequently use medications with anticholinergic properties (bladder medications, certain antidepressants, antihistamines). Anticholinergic burden increases confusion risk independently, and combining it with eszopiclone's CNS depression compounds delirium vulnerability.

Alternatives to Eszopiclone in Adults 65 and Older

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for Chronic Insomnia Disorder recommends CBT-I as the first-line treatment for all adults, explicitly noting that the evidence base in older adults supports CBT-I over pharmacotherapy [14].

First-Line: Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I combines sleep restriction, stimulus control, sleep hygiene, and cognitive restructuring. A meta-analysis in Annals of Internal Medicine (N=2,189 participants across 20 trials) found CBT-I reduced wake-after-sleep-onset by 55 minutes and reduced sleep-onset latency by 19 minutes, with effects maintained at 12-month follow-up [15]. Gains in older adults were equivalent to those in younger cohorts.

Digital CBT-I programs (dCBT-I), including Sleepio and Somryst (FDA-cleared), deliver the intervention without in-person access, which matters for older adults with mobility limitations.

Lower-Risk Pharmacologic Options

When pharmacotherapy is genuinely necessary, the following agents carry relatively better profiles in older adults:

• Low-dose doxepin (3 mg or 6 mg): FDA-approved for sleep maintenance insomnia, minimal next-day impairment at these doses, not a PIM in the Beers Criteria. A randomized trial (N=240, mean age 63) showed significant improvement in wake-after-sleep-onset vs. Placebo without psychomotor impairment [16].
• Melatonin receptor agonist ramelteon: Not a controlled substance, no dependence liability, no next-day impairment data of concern, though efficacy is modest.
• Suvorexant (Belsomra) or lemborexant (Dayvigo): Orexin receptor antagonists with a different mechanism, no GABA-A activity. Lemborexant 2.5 mg is considered by some geriatricians to have a more favorable next-day impairment profile than eszopiclone, though head-to-head geriatric data are limited.

Melatonin at 0.5 to 3 mg taken 30 to 60 minutes before the target sleep time may also help with circadian-related sleep changes common after 65.

Prescribing Eszopiclone in Older Adults: A Safe-Use Protocol

When eszopiclone is chosen after non-pharmacologic options have been tried, a structured prescribing approach reduces risk.

Dose and Duration

• Start at 1 mg. Do not exceed 1 mg in adults 65 and older, per FDA labeling [2].
• Prescribe for the shortest necessary duration. The FDA approval language supports up to 6 months of controlled clinical trial data, but clinical practice should reassess at 2 to 4 weeks.
• Use the lowest available tablet form to enable precise tapering if needed.

Monitoring Parameters

At each visit while the patient takes eszopiclone, assess:

1. Daytime sedation and next-morning alertness
2. Any new fall or near-fall event
3. Cognitive status change (brief cognitive screen such as the MoCA or MMSE at baseline and 3-month intervals)
4. Medication reconciliation for new CYP3A4 inhibitors or CNS depressants

Discontinuation Triggers

Stop eszopiclone promptly if any of the following occur: a fall attributed to sedation, a new diagnosis of MCI or dementia, new opioid prescription, hospitalization, or patient preference to discontinue.

A structured 6 to 10 week taper with concurrent CBT-I referral is the preferred exit strategy in patients who have used the drug for more than 4 weeks.